Regeneron signs $2.32 billion deal with Parabilis for Helicon conjugates
The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon peptide platform
The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon peptide platform
The therapy is suited for patients with severe valve leakage who face elevated surgical risk due to advanced age, frailty, or multiple medical complications
The new facility at Byatarayanapura introduces Karnataka’s first Elekta Unity MR-Linac technology
Discussions during the meeting focused on strengthening India’s preparedness against zoonotic diseases and climate-sensitive health challenges
Union health ministry secretary Punya Salila Srivastava lauds HLL’s six decades of contribution to public healthcare and social development
Growth was driven by expansion across key business segments, improving efficiencies, and sustained demand across institutional and retail channels
Despite the strong results, investigators cautioned that the study has limitations, including its open-label Phase II design, lack of randomization, and reliance on a historical external control arm
According to the analysis, just 23% of patients aged 18–29 were formally diagnosed with TD
Baxfendy works in a fundamentally different way from current therapies
Subscribe To Our Newsletter & Stay Updated